• Search History (Register)
  • MeSH Browser
    • Afrikaans
      Albanian
      Arabic
      Armenian
      Basque
      Bengali
      Bulgarian
      Catalan
      Cambodian
      Chinese (Mandarin)
      Chinese (Cantonese)
      Croatian
      Czech
      Danish
      Dutch
      English
      Estonian
      Fiji
      Finnish
      French
      Georgian
      German
      Greek
      Gujarati
      Hebrew
      Hindi
      Hungarian
      Icelandic
      Indonesian
      Irish
      Italian
      Japanese
      Javanese
      Korean
      Latin
      Latvian
      Lithuanian
      Macedonian
      Malay
      Malayalam
      Maltese
      Maori
      Marathi
      Mongolian
      Nepali
      Norwegian
      Persian
      Polish
      Portuguese
      Punjabi
      Quechua
      Romanian
      Russian
      Samoan
      Serbian
      Slovak
      Slovenian
      Spanish
      Swahili
      Swedish
      Tamil
      Tatar
      Telugu
      Thai
      Tibetan
      Tonga
      Turkish
      Ukrainian
      Urdu
      Uzbek
      Vietnamese
      Welsh
      Xhosa
      Apply
    • Adelaide Health Technology Assessment
      Agence d'évaluation des technologies et des modes d'intervention en santé
      Agencia de Evaluacion de Tecnologias Sanitarias
      Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)
      Agencia de Qualitat i Avaluacio Sanitries de Catalunya
      Agency for Care Effectiveness (ACE)
      Agency for Health Technology Assessment and Tariff System
      Agency for Healthcare Research and Quality
      Agenzia Sanitaria e Sociale Regionale (Regional Agency for Health and Social Care)
      All Wales Medicines Strategy Group
      Andalusian Health Technology Assessment Area
      Australian Health Technology Advisory Committee
      Australian Safety and Efficacy Register of New Interventional Procedures-Surgical
      Austrian Institute for Health Technology Assessment
      Basque Office for Health Technology Assessment
      Belgian Health Care Knowledge Centre
      BlueCross BlueShield Association
      British Columbia Office of Health Technology Assessment
      Canadian Agency for Drugs and Technologies in Health
      Canadian Coordinating Office for Health Technology Assessment
      Canadian Task Force on Preventive Health Care
      Canary Health Service
      Cellule Innovation of the AP-HP
      Center for Drug Evaluation
      Center for Medical Technology Assessment
      Center for Outcomes Research and Economic Evaluation for Health
      Centre for Clinical Effectiveness
      Centre for Reviews and Dissemination
      Centre for Technology Assessment at the Swiss Science and Technology Council
      Centre Hospitalier de l'Universite de Montreal
      Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale
      Committee for New Health Technology Assessment
      Conseil d'Evaluation des Technologies de la Santé du Québec
      Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
      Danish Centre for Evaluation and Health Technology Assessment
      Danish Institute for Health Services Research
      ECRI Institute
      European Network for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore
      German Agency for HTA at the German Institute for Medical Documentation and Information
      Gesundheit Osterreich GmbH
      Hannover Medical School, Medizinische Hochschule Hannover
      Haute Autorité de Santé
      HAYES, Inc.
      Health Council of the Netherlands Gezondheidsraad
      Health Information and Quality Authority (HIQA)
      Health Intervention and Technology Assessment Program
      Health Quality Ontario
      Health Sciences Institute in Aragon (IACS)
      Health Services Assessment Collaboration
      Health Services Utilization and Research Commission
      Health Technology Advisory Committee
      Health Technology and Policy Unit
      Health Technology Assessment Section, Ministry of Health Malaysia
      Health Technology Board for Scotland
      Health Technology Reference Group
      Health Technology Wales
      HTA Region Stockholm
      HTA South
      HTA Unit, University of Calgary
      Institut national d'excellence en sante et en services sociaux
      Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)
      Institute for Clinical and Economic Review
      Institute for Clinical Effectiveness and Health Policy
      Institute for Clinical Evaluative Sciences
      Institute for Clinical Systems Improvement
      Institute for Quality and Efficiency in Health Care (IQWiG)
      Institute of Applied Health Sciences
      Institute of Health Economics
      Institute of Health Economics
      Institute of Health Technology Assessment and Research (IETSI)
      Institute of Technology Assessment
      Israel Center for Technology Assessment in Health Care
      L'Agence Nationale d'Accreditation d'Evaluation en Santé
      Ludwig Boltzmann Institute for Health Technology Assessment
      Malaysian Health Technology Assessment
      Malaysian Health Technology Assessment Unit
      Medical Advisory Secretariat
      Medical Services Advisory Committee
      Monash Business School, Monash University (MBS)
      National Authority for Assessment and Accreditation in Healthcare (INEAS)
      National Committee for Technology Incorporation (CONITEC)
      National Evidence-based healthcare Collaborating Agency
      National Institute for Clinical Excellence
      National Institute for Health and Care Excellence
      New Zealand Health Technology Assessment
      New Zealand National Health Committee
      NIHR Health and Social Care Delivery Program
      NIHR Health Services and Delivery Research programme
      NIHR Health Technology Assessment programme
      NIHR Horizon Scanning Centre
      NIHR Public Health Research programme
      Norwegian Institute of Public Health
      Norwegian Institute of Public Health
      Norwegian Medical Products Agency
      Ontario Health
      Penn Medicine Center for Evidence-based Practice
      Quality Improvement Scotland
      Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
      Scottish Health Purchasing Information Centre
      Scottish Health Technologies Group
      Scottish Medicines Consortium (SMC)
      State Health Care Accreditation Agency under the Ministry of Health of the Republic of Lithuania
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swiss Federal Office of Public Health (FOPH)
      Technology Assessment at SickKids
      Technology Assessment Unit of the McGill University Health Centre (MUHC)
      The Danish Health Technology Council
      The Federal Joint Committee
      The HTA Center of the Stockholm County Council/Gotland
      The Italian National Agency for Regional Health Services (Agenas)
      The National Health Care Institute (ZIN, Zorginstituut Nederland)
      The National Health Care Institute (Zorginstituut Nederland)
      The Netherlands Organisation for Health Research and Development
      The Regional Health Technology Assessment Centre
      TNO
      U. S. Congress. Office of Technology Assessment
      Unidad de Evaluacion de Tecnologias Sanitarias
      Unidad de Tecnologias de Salud
      Unit of Health Economics and Technology Assessment in Health Care
      University HealthSystem Consortium
      University of York
      VA Technology Assessment Program
      Washington Singer Press
      Washington State Department of Labor and Industries (WSDLI)
      Wessex Institute for Health Research and Development
      West Midlands Health Technology Assessment Collaboration
      WorkSafeBC
      Apply
    • Afghanistan
      Albania
      Algeria
      Andorra
      Antigua and Barbuda
      Argentina
      Armenia
      Australia
      Austria
      Azerbaijan
      Bahamas
      Bahrain
      Bangladesh
      Barbados
      Belarus
      Belgium
      Belize
      Benin
      Bhutan
      Bolivia
      Bosnia and Herzegovina
      Botswana
      Brazil
      Brunei
      Bulgaria
      Burkina Faso
      Burundi
      Cambodia
      Cameroon
      Canada
      Cape Verde
      Central African Republic
      Chad
      Chile
      China
      Colombia
      Comoros
      Congo
      Costa Rica
      Cote dIvoire
      Croatia
      Cuba
      Cyprus
      Czech Republic
      Denmark
      Djibouti
      Dominica
      Dominican Republic
      East Timor
      Ecuador
      Egypt
      El Salvador
      Equatorial Guinea
      Eritrea
      Estonia
      Ethiopia
      Fiji
      Finland
      France
      Gabon
      Gambia
      Georgia
      Germany
      Ghana
      Greece
      Grenada
      Guatemala
      Guinea
      Guinea-Bissau
      Guyana
      Haiti
      Honduras
      Hong Kong
      Hungary
      Iceland
      India
      Indonesia
      Iran
      Iraq
      Ireland
      Israel
      Italy
      Jamaica
      Japan
      Jordan
      Kazakhstan
      Kenya
      Kiribati
      North Korea
      South Korea
      Kuwait
      Kyrgyzstan
      Laos
      Latvia
      Lebanon
      Lesotho
      Liberia
      Libya
      Liechtenstein
      Lithuania
      Luxembourg
      Macedonia
      Madagascar
      Malawi
      Malaysia
      Maldives
      Mali
      Malta
      Marshall Islands
      Mauritania
      Mauritius
      Mexico
      Micronesia
      Moldova
      Monaco
      Mongolia
      Montenegro
      Morocco
      Mozambique
      Myanmar
      Namibia
      Nauru
      Nepal
      Netherlands
      New Zealand
      Nicaragua
      Niger
      Nigeria
      Norway
      Oman
      Pakistan
      Palau
      Panama
      Papua New Guinea
      Paraguay
      Peru
      Philippines
      Poland
      Portugal
      Puerto Rico
      Qatar
      Romania
      Russia
      Rwanda
      Saint Kitts and Nevis
      Saint Lucia
      Saint Vincent and the Grenadines
      Samoa
      San Marino
      Sao Tome and Principe
      Saudi Arabia
      Senegal
      Serbia and Montenegro
      Seychelles
      Sierra Leone
      Singapore
      Slovakia
      Slovenia
      Solomon Islands
      Somalia
      South Africa
      Spain
      Sri Lanka
      Sudan
      Suriname
      Swaziland
      Sweden
      Switzerland
      Syria
      Taiwan
      Tajikistan
      Tanzania
      Thailand
      Togo
      Tonga
      Trinidad and Tobago
      Tunisia
      Turkey
      Turkmenistan
      Tuvalu
      Uganda
      Ukraine
      United Arab Emirates
      United Kingdom
      United States
      Uruguay
      Uzbekistan
      Vanuatu
      Vatican City
      Venezuela
      Vietnam
      Yemen
      Zambia
      Zimbabwe
      Apply

Welcome to the international HTA database

CSV RIS
Showing [23755 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dapagliflozin (heart failure with LVEF > 40 %) – Addendum to Commission A23-11]
2023     NIHR Health Technology Assessment programme Implementing early rehabilitation and mobilisation for children in UK paediatric intensive care units: the PERMIT feasibility study
2023     Agency for Care Effectiveness (ACE) KardiaMobile for the detection of atrial fibrillation
2023     Center for Drug Evaluation (CDE) [Assessment of the optimal implementation strategy for pneumococcal vaccination policies in groups at high risk of invasive pneumococcal disease]
2023     Canary Health Service [Clinical effectiveness and cost-effectiveness of the extension of colorectal cancer screening up to 74 years of age in general population]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: Zemaira - congenital alpha1- antitrypsin deficiency]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Belantamab mafodotin (multiple myeloma) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V (expiry of the decision)]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Penile traction therapy for induratio penis plastica]
2023     Health Sciences Institute in Aragon (IACS) [Molecular study of common apoE gene polymorphisms associated with familial dysbetalipoproteinaemia and late-onset Alzheimer’s disease]
2023     Canary Health Service [Effectiveness, safety and cost-effectiveness of real time continuous glucose monitoring systems, open-loop systems and hybrid closed-loop systems (artificial pancreas) for patients with diabetes]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: optimal use of echocardiography in Québec- diagnosis and follow-up of chronic heart failure]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: Glassia – congenital alpha1- antitrypsin deficiency]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Exagamglogene autotemcel (transfusion-dependent β-thalassaemia) - Assessment according to §35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nivolumab (NSCLC, combination with platinum-based chemotherapy, neoadjuvant) – Benefit assessment according to §35a Social Code Book V]
2023     Canary Health Service [Melanoma detection without biopsy using a non-invasive adhesive patch]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: Prolastin-C Liquid – congenital alpha1-antitrypsin deficiency]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tabelecleucel (relapsed or refractory Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD), pretreated, 2 years and older) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Mavacamten (cardiomyopathy) – Benefit assessment according to §35a Social Code Book V]
2023     Canary Health Service [Cost-effectiveness of systematic vaccination against invasive meningococcal disease due to serogroup B in childhood]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: relevant practices for promoting hearing health in long-term residential care settings]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Etranacogene dezaparvovec (haemophilia B) - Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Eftrenonacog alfa (haemophilia B) – Benefit assessment according to §35a Social Code Book V]
2023     Canary Health Service [Neuropsychological rehabilitation in people with paediatric cancer]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Setmelanotide (Bardet Biedl syndrome) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Empagliflozin (renal insufficiency) - Benefit assessment according to § 35a Social Code Book V]
2023     Canary Health Service [Determination by chemiluminescence of autoantibodies to domain 1 of beta 2 glycoprotein I in patients with antiphospholipid syndrome]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [State of practice: developing portraits to support the ongoing adaptation of youth services by local service networks]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Olaparib (prostate cancer) – Second Addendum to Commission A23-03]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cipaglucosidase alfa (Pompe disease) – Benefit assessment according to § 35a Social Code Book (SGB) V]
2023     Canary Health Service [Cost-effectiveness of childhood vaccination against invasive meningococcal disease due to ACWY serogroups]
2023     Health Information and Quality Authority (HIQA) Repatriation of paediatric haematopoietic stem cell transplant services to Ireland: a Health Technology Assessment
2023     NIHR Health Technology Assessment programme Bleeding risk in patients prescribed dual antiplatelet therapy and triple therapy after coronary interventions: the ADAPTT retrospective population-based cohort studies
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Exagamglogene (ß-thalassaemia in patients ≥ 12 years); assessment according to §35a Social Code Book V; search for disease registries]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Trifluridine/tipiracil (combination with bevacizumab; colorectal cancer) – Benefit assessment according to §35a Social Code Book V]
2023     Health Information and Quality Authority (HIQA) A rapid health technology assessment of gene expression profiling tests for guiding the use of adjuvant chemotherapy in early-stage invasive breast cancer
2023     NIHR Health Technology Assessment programme Antibiotics for lower respiratory tract infection in children presenting in primary care: ARTIC-PC RCT
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Decision aid for gallbladder removal]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sacituzumab govitecan (breast cancer) – Benefit assessment according to §35a Social Code Book V]
2023     Norwegian Institute of Public Health (NIPH) Transcutaneous non-invasive vagus nerve stimulation (gammaCore) for the treatment of cluster headache: A single technology assessment
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Relationship between volume of services and quality in revision surgery (knee)]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: Rebinyn – prophylaxis in children and adolescents with hemophilia B]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: measurement and monitoring of total serum bilirubin in a newborn with signs suggestive of neonatal jaundice]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence search for the S3 guideline on advice for vitamin D substitution]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Migalastat (Fabry disease) – Benefit assessment according to §35a Social Code Book V]
2023     Basque Office for Health Technology Assessment (OSTEBA) [Massive parallel sequencing for the diagnosis of acute leukaemia]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: next-generation sequencing (NGS) panels for intellectual disability and global developmental delay - Assessment report on the repatriation of a test performed outside Québec]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: rapid assessment zones in emergency departments - organizational characteristics and their impact]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Routine practice data collection for brexucabtagene autoleucel acc. to the Law for More Safety in the Supply of Medicines (GSAV): Evaluation of the study protocol (Version 3.0) and the statistical analysis plan (Version 3.0) – Fourth addendum to Commission]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: characteristics and needs of targeted rehabilitation clienteles for young people with adjustment problems aged 10 or older]
2023     NIHR Health Services and Delivery Research programme Factors which facilitate or impede patient engagement with pulmonary and cardiac rehabilitation: a rapid evaluation mapping review
2023     Austrian Institute for Health Technology Assessment (AIHTA) [Economic dimensions of community nursing: A systematic literature review]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nonacog beta pegol (haemophilia B, children < 12 years) – Benefit assessment according to §35a Social Code Book V]
2023     Norwegian Institute of Public Health (NIPH) Stockholm3 test to estimate the risk of prostate cancer: a single technology assessment
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: effectiveness of rehabilitation models and approaches for young people with adjustment problems]
2023     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) The clinical effectiveness of denosumab (Prolia) in patients with hormone-sensitive cancer receiving endocrine therapy, compared to bisphosphonates, selective estrogen receptor modulators (SERM), and placebo: a systematic review and network meta-analysis
2023     NIHR Health Services and Delivery Research programme A multimethod study of NHS 111 online
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Teclistamab (multiple myeloma) – Benefit assessment according to §35a Social Code Book V]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [State of practice: continuum of care and services for individuals with a traumatic spinal cord injury in Québec - characteristics, care pathways and clinical outcomes for adults from 2014 to 2020]
2023     NIHR Health Services and Delivery Research programme Thinking ahead about medical treatments in advanced illness: a qualitative study of barriers and enablers in end-of-life care planning with patients and families from ethnically diverse backgrounds
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Vosoritide (achondroplasia, ≥ 2 years) – Benefit assessment according to §35a Social Code Book V]
2023     HTA Region Stockholm [Effects of nonsteroidal anti-inflammatory drugs (NSAID) on risk of exacerbation of disease in patients with inflammatory bowel disease (IBD)]
2023     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Eladocagene exuparvovec (Aromatic-L-amino acid decarboxylase (AADC) deficiency, ≥ 18 months)]
2023     NIHR Health Services and Delivery Research programme Towards achieving interorganisational collaboration between health-care providers: a realist evidence synthesis
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tixagevimab/cilgavimab (pre-exposure prophylaxis of COVID-19) – Addendum to Commission A23-42]
2023     NIHR Health Services and Delivery Research programme Early evaluation of the Children and Young People's Mental Health Trailblazer programme: a rapid mixed-methods study
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lisocabtagene maraleucel (DLBCL, HGBL, PMBCL and FL3B, second line) – Addendum to Commission A23-48]
2023     Center for Outcomes Research and Economic Evaluation for Health (C2H) [Cost-effectiveness evaluation of Efgartigimod Alfa (Vyvgart)]
2023     NIHR Health Services and Delivery Research programme New and emerging technology for adult social care - the example of home sensors with artificial intelligence (AI) technology
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sacubitril/valsartan (heart failure, children and adolescents) – Addendum to Commission A23-56]
2023     Center for Outcomes Research and Economic Evaluation for Health (C2H) (Cost-effectiveness evaluation of Valbenazine (Dysval) for tardive dyskinesia)
2023     NIHR Health Services and Delivery Research programme Youth violence intervention programme for vulnerable young people attending emergency departments in London: a rapid evaluation
2023     Center for Outcomes Research and Economic Evaluation for Health (C2H) [Cost-effectiveness evaluation of andexanet alfa (Ondexxya)]
2023     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Evaluation of early intervention programs in psychosis targeting adolescents and young adults]
2023     NIHR Health Services and Delivery Research programme The effects of computerised decision support systems on nursing and allied health professional performance and patient outcomes: a systematic review and user contextualisation
2023     Center for Outcomes Research and Economic Evaluation for Health (C2H) [Cost-effectiveness evaluation of clazosentan (Pivlaz)]
2023     Austrian Institute for Health Technology Assessment (AIHTA) [Radiofrequency denervation for chronic lumbar or cervical spine pain]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Glofitamab (diffuse large B-cell lymphoma) – Assessment according to § 35a Social Code Book (SGB) V (1) Sentence 11]
2023     Austrian Institute for Health Technology Assessment (AIHTA) Percutaneous mitral valve repair with a clip device in patients with mitral regurgitation. Update 2023
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Bedaquiline (tuberculosis) – Assessment according to § 35a (1), Sentence 11, Social Code Book (SGB) V]
2023     Austrian Institute for Health Technology Assessment (AIHTA) Allogeneic mesenchymal stem cells for Crohn's disease-associated complex perianal fistulas. Update 2023
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dalbavancin (acute bacterial infections of the skin and the soft tissue, = 3 months) - Assessment according to § 35a (1c), Social Code Book (SGB) V]
2023     Center for Outcomes Research and Economic Evaluation for Health (C2H) [Cost-effectiveness evaluation of gefapixant (Lyfnua)]
2023     Austrian Institute for Health Technology Assessment (AIHTA) 177Lu-PSMA radioligand therapy in patients with metastatic castration-resistant prostate cancer: Update 2023 - systematic review
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tisagenlecleucel (ALL) – Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2023     Center for Outcomes Research and Economic Evaluation for Health (C2H) [Cost-effectiveness evaluation of bimekizumab (Bimzelx)]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Loncastuximab tesirine (DLBCL and HGBL) – Addendum to Commission A23-45]
2023     Norwegian Institute of Public Health (NIPH) [Surgery for degenerative rotator cuff tears: a health technology assessment]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on oropharyngeal dysphagia due to head and neck tumours – diagnosis and treatment: Triage tests in the context of dysphagia diagnostics]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Odronextamab (follicular lymphoma in adults); assessment according to §35a Social Code Book V; search for disease registries]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on oropharyngeal dysphagia due to head and neck tumours – diagnosis and treatment: Self-evaluation of swallowing behaviour]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Odronextamab (diffuse large B-cell lymphoma in adults); assessment according to §35a Social Code Book V; search for disease registries]
2023     Austrian Institute for Health Technology Assessment (AIHTA) Percutaneous aspiration thrombectomy for pulmonary embolism
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on oropharyngeal dysphagia due to head and neck tumours – diagnosis and treatment: Prophylactic percutaneous endoscopic gastrostomy tube]
2023     Agency for Care Effectiveness (ACE) Daratumumab for treating newly diagnosed light chain (AL) amyloidosis
2023     Austrian Institute for Health Technology Assessment (AIHTA) Transcranial magnetic resonance-guided high-intensity focused ultrasound treatment in patients with drug-resistant essential tremor
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on oropharyngeal dysphagia due to head and neck tumours – diagnosis and treatment: Intensity-modulated radiotherapy under consideration of swallowing function]
2023     Institute for Clinical and Economic Review (ICER) Oral and monoclonal antibody treatments for relapsing forms of multiple sclerosis: effectiveness and value
2023     Agency for Care Effectiveness (ACE) Inhaled corticosteroids with long acting beta-2 agonists for treating asthma
2023     Austrian Institute for Health Technology Assessment (AIHTA) Bleomycin electrosclerotherapy for vascular anomalies
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on oropharyngeal dysphagia due to head and neck tumours – diagnosis and treatment: tumour resection]